Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tamoxifen + Femoston
- Development stage
- Preclinical
- Lead developer
- AkzoNobel
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of tamoxifen (a selective estrogen receptor modulator) and Femoston (a hormone replacement therapy containing estradiol and dydrogesterone). This combination has been studied for use in patients with thin endometrium undergoing frozen embryo transfer cycles, where tamoxifen appears to improve endometrial thickness when used alongside hormone replacement therapy.
02
Targets
ESR2 (ERβ)ESR1 (ERα)
Beyond the preview
Go deeper on tamoxifen + Femoston.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tamoxifen + Femoston.